Brain iron metabolism and its perturbation in neurological diseases
- PMID: 20809066
- DOI: 10.1007/s00702-010-0470-z
Brain iron metabolism and its perturbation in neurological diseases
Abstract
Metal ions are of particular importance in brain function, notably iron. A broad overview of iron metabolism and its homeostasis both at the cellular level (involving regulation at the level of mRNA translation) and the systemic level (involving the peptide 'hormone' hepcidin) is presented. The mechanisms of iron transport both across the blood-brain barrier and within the brain are then examined. The importance of iron in the developing foetus and in early life is underlined. We then review the growing corpus of evidence that many neurodegenerative diseases (NDs) are the consequence of dysregulation of brain iron homeostasis. This results in the production of reactive oxygen species, generating reactive aldehydes, which, together with further oxidative insults, causes oxidative modification of proteins, manifested by carbonyl formation. These misfolded and damaged proteins overwhelm the ubiquitin/proteasome system, accumulating the characteristic inclusion bodies found in many NDs. The involvement of iron in Alzheimer's disease and Parkinson's disease is then examined, with emphasis on recent data linking in particular interactions between iron homeostasis and key disease proteins. We conclude that there is overwhelming evidence for a direct involvement of iron in NDs.
Similar articles
-
The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects.Biomed Pharmacother. 2024 Oct;179:117419. doi: 10.1016/j.biopha.2024.117419. Epub 2024 Sep 8. Biomed Pharmacother. 2024. PMID: 39245001 Review.
-
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.J Neurochem. 2016 Oct;139 Suppl 1:179-197. doi: 10.1111/jnc.13425. Epub 2016 Feb 10. J Neurochem. 2016. PMID: 26545340 Review.
-
Impaired iron homeostasis in Parkinson's disease.J Neural Transm Suppl. 2000;(60):37-58. doi: 10.1007/978-3-7091-6301-6_3. J Neural Transm Suppl. 2000. PMID: 11205155 Review.
-
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.Free Radic Biol Med. 2013 Sep;62:52-64. doi: 10.1016/j.freeradbiomed.2013.01.017. Epub 2013 Jan 30. Free Radic Biol Med. 2013. PMID: 23376471 Review.
-
Neurodegenerative diseases and therapeutic strategies using iron chelators.J Trace Elem Med Biol. 2015;31:267-73. doi: 10.1016/j.jtemb.2014.12.012. Epub 2015 Jan 22. J Trace Elem Med Biol. 2015. PMID: 25716300 Review.
Cited by
-
Significant glial alterations in response to iron loading in a novel organotypic hippocampal slice culture model.Sci Rep. 2016 Nov 3;6:36410. doi: 10.1038/srep36410. Sci Rep. 2016. PMID: 27808258 Free PMC article.
-
Effects of Resistance Exercise on Cerebral Redox Regulation and Cognition: An Interplay Between Muscle and Brain.Antioxidants (Basel). 2019 Nov 6;8(11):529. doi: 10.3390/antiox8110529. Antioxidants (Basel). 2019. PMID: 31698763 Free PMC article. Review.
-
The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice.Int J Nanomedicine. 2014 Aug 11;9:3841-53. doi: 10.2147/IJN.S64630. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25143732 Free PMC article.
-
The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells.PLoS One. 2021 Jul 26;16(7):e0254794. doi: 10.1371/journal.pone.0254794. eCollection 2021. PLoS One. 2021. PMID: 34310628 Free PMC article.
-
Prevalence of iron deficiency in a South African adolescent inpatient psychiatric population: Rates, risk factors and recommendations.S Afr J Psychiatr. 2019 Jul 16;25:1347. doi: 10.4102/sajpsychiatry.v25i0.1347. eCollection 2019. S Afr J Psychiatr. 2019. PMID: 31404366 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical